Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 9.1% in the fourth quarter, Holdings Channel reports. The firm owned 10,858 shares of the specialty pharmaceutical company’s stock after buying an additional 909 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Supernus Pharmaceuticals were worth $314,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Mystic Asset Management Inc. raised its holdings in shares of Supernus Pharmaceuticals by 1.7% in the third quarter. Mystic Asset Management Inc. now owns 29,840 shares of the specialty pharmaceutical company’s stock worth $823,000 after buying an additional 500 shares during the last quarter. Assetmark Inc. lifted its position in Supernus Pharmaceuticals by 2.3% during the 3rd quarter. Assetmark Inc. now owns 28,578 shares of the specialty pharmaceutical company’s stock worth $788,000 after acquiring an additional 629 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in Supernus Pharmaceuticals by 96.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,401 shares of the specialty pharmaceutical company’s stock valued at $39,000 after purchasing an additional 687 shares during the last quarter. Teacher Retirement System of Texas increased its holdings in shares of Supernus Pharmaceuticals by 4.9% in the third quarter. Teacher Retirement System of Texas now owns 15,470 shares of the specialty pharmaceutical company’s stock valued at $427,000 after purchasing an additional 718 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Supernus Pharmaceuticals by 3.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 23,809 shares of the specialty pharmaceutical company’s stock worth $689,000 after purchasing an additional 872 shares during the last quarter.

Analyst Ratings Changes

Separately, Piper Sandler dropped their target price on Supernus Pharmaceuticals from $45.00 to $41.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 28th.

Insider Activity at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $30.21, for a total value of $151,050.00. Following the sale, the vice president now owns 8,570 shares in the company, valued at approximately $258,899.70. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 5,000 shares of Supernus Pharmaceuticals stock in a transaction on Monday, February 26th. The shares were sold at an average price of $30.21, for a total value of $151,050.00. Following the completion of the transaction, the vice president now owns 8,570 shares of the company’s stock, valued at $258,899.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Padmanabh P. Bhatt sold 12,364 shares of the stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $35.31, for a total transaction of $436,572.84. Following the sale, the vice president now directly owns 8,570 shares in the company, valued at $302,606.70. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 35,739 shares of company stock worth $1,227,433. 8.76% of the stock is owned by corporate insiders.

Supernus Pharmaceuticals Price Performance

Shares of Supernus Pharmaceuticals stock opened at $30.83 on Monday. The firm has a fifty day moving average price of $31.72 and a 200 day moving average price of $28.78. Supernus Pharmaceuticals, Inc. has a 1 year low of $21.99 and a 1 year high of $38.08.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.39). The company had revenue of $164.30 million for the quarter, compared to analysts’ expectations of $155.03 million. Supernus Pharmaceuticals had a net margin of 0.22% and a return on equity of 0.14%. The business’s quarterly revenue was down 1.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.43 EPS. As a group, equities analysts expect that Supernus Pharmaceuticals, Inc. will post 1.16 EPS for the current year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.